TIVDAK (tisotumab vedotin-tftv)
ANTINEOPLAS-TISSUE FACTOR DIRECTED AB-MICROTUB DISRUPT CONJ · CARCINOMA OF CERVIX
SEATTLE GENETIC
Drug class
Antineoplas-Tissue Factor Directed Ab-Microtub Disrupt Conj
The phrase "Antineoplas-Tissue Factor Directed Ab-Microtub Disrupt Conj" is an abbreviated formulary or administrative classification describing antineoplastic tissue factor-directed antibody and microtubule disruptor conjugates. Read more about Antineoplas-Tissue Factor Directed Ab-Microtub Disrupt Conj
2 drugs in this class 2 manufacturers
Drugs in Antineoplas-Tissue Factor Directed Ab-Microtub Disrupt Conj
TIVDAK (tisotumab vedotin-tftv)
ANTINEOPLAS-TISSUE FACTOR DIRECTED AB-MICROTUB DISRUPT CONJ · CARCINOMA OF CERVIX
SEAGEN/PFIZER
Filter & compare in the drug finder →
Opens the drug finder with Antineoplas-Tissue Factor Directed Ab-Microtub Disrupt Conj preselected. Add indication or manufacturer filters there.
The phrase "Antineoplas-Tissue Factor Directed Ab-Microtub Disrupt Conj" is an abbreviated formulary or administrative classification describing antineoplastic tissue factor-directed antibody and microtubule disruptor conjugates.
Rather than a broad pharmacological family, this specialized category currently represents targeted antibody-drug conjugates exemplified by tisotumab vedotin.
Agents in this class consist of a monoclonal antibody targeting cell-surface tissue factor linked to an antimitotic cytotoxic payload, such as monomethyl auristatin E, which inhibits tubulin polymerization and causes cell cycle arrest and apoptosis upon cellular internalization.
Therapeutics in this group are primarily utilized in oncology for the treatment of adult patients with recurrent or metastatic cervical cancer that has progressed on or following systemic chemotherapy.
-
fda.gov
The phrase "Antineoplas-Tissue Factor Directed Ab-Microtub Disrupt Conj" is an abbreviated formulary or administrative classification describing antineoplastic tissue factor-directed antibody and microtubule disruptor conjugates Rather than a broad pharmacological family, this specialized category currently represents targeted antibody-drug conjugates exemplified by tisotumab vedotin Therapeutics in this group are primarily utilized in oncology for the treatment of adult patients with recurrent ...
-
pfizer.com
The phrase "Antineoplas-Tissue Factor Directed Ab-Microtub Disrupt Conj" is an abbreviated formulary or administrative classification describing antineoplastic tissue factor-directed antibody and microtubule disruptor conjugates
-
nih.gov
Rather than a broad pharmacological family, this specialized category currently represents targeted antibody-drug conjugates exemplified by tisotumab vedotin Agents in this class consist of a monoclonal antibody targeting cell-surface tissue factor linked to an antimitotic cytotoxic payload, such as monomethyl auristatin E, which inhibits tubulin polymerization and causes cell cycle arrest and apoptosis upon cellular internalization
-
nih.gov
Agents in this class consist of a monoclonal antibody targeting cell-surface tissue factor linked to an antimitotic cytotoxic payload, such as monomethyl auristatin E, which inhibits tubulin polymerization and causes cell cycle arrest and apoptosis upon cellular internalization Therapeutics in this group are primarily utilized in oncology for the treatment of adult patients with recurrent or metastatic cervical cancer that has progressed on or following systemic chemotherapy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.